Outcome in PCNSL patients and its association with PD-L1+ leukocytes in the tumor microenvironment

References

• Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. : International Agency for Research on Cancer (IARC) 2016.
   Google Scholar
• Eloranta S, Branvall E, Celsing F, et al. Increasing incidence of primary Central nervous system lymphoma but no improvement in survival in Sweden 2000-2013. Eur J Haematol. 2018;100(1):61–68.
   PubMed Web of Science ®Google Scholar
• Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. NEUONC. 2016;18(9):1297–1303.
   Google Scholar
• Villa D, Tan KL, Steidl C, et al. Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. Blood Adv. 2019;3(23):3953–3961.
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–196.
   PubMed Web of Science ®Google Scholar
• Ge L, Lu S, Xu L, et al. MYC, BCL2, and BCL6 expression as prognostic indicators in primary Central nervous system lymphoma: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2021;208:106838.
   PubMedGoogle Scholar
• Xie W, Medeiros LJ, Li S, et al. PD-1/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep. 2020;15(4):372–381.
   PubMedGoogle Scholar
• Hatic H, Sampat D, Goyal G. Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Ann Transl Med. 2021;9(12):1037.
   PubMedGoogle Scholar
• Wu RY, Kong PF, Xia LP, et al. Regorafenib promotes antitumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma. Clin Cancer Res. 2019;25(14):4530–4541.
   PubMed Web of Science ®Google Scholar
• Epacadostat shows value in two SCCHN trials. Cancer Discovery. 2017;7(9):OF2.
   Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary Central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3073.
   PubMed Web of Science ®Google Scholar
• Furuse M, Kuwabara H, Ikeda N, et al. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary Central nervous system lymphoma. BMC Cancer. 2020;20(1):277.
   PubMed Web of Science ®Google Scholar
• Hayano A, Komohara Y, Takashima Y, et al. Programmed cell death ligand 1 expression in primary Central nervous system lymphomas: a clinicopathological study. Anticancer Res. 2017;37(10):5655–5666.
   PubMed Web of Science ®Google Scholar
• Abdulla M, Alexsson A, Sundstrom C, et al. PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS. Acta Oncol. 2021;60(4):531–538.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Chen S, Crabill GA, Pritchard TS, et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305.
   PubMed Web of Science ®Google Scholar
• Yearley JH, Gibson C, Yu N, et al. PD-L2 expression in human tumors: Relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158–3167.
   PubMed Web of Science ®Google Scholar
• Cho H, Kim SH, Kim SJ, et al. Programmed cell death 1 expression is associated with inferior survival in patients with primary Central nervous system lymphoma. Oncotarget. 2017;8(50):87317–87328.
   PubMedGoogle Scholar
• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–2418.
   PubMed Web of Science ®Google Scholar
• Grommes C, Rubenstein JL, DeAngelis LM, et al. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019;21(3):296–305.
   PubMedGoogle Scholar
• Miyasato Y, Takashima Y, Takeya H, et al. The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary Central nervous system lymphoma. J Clin Exp Hematop. 2018;58(2):95–101.
   PubMed Web of Science ®Google Scholar
• Hattab EM, Martin SE, Al-Khatib SM, et al. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Mod Pathol. 2010;23(2):235–243.
   PubMedGoogle Scholar
• Montesinos-Rongen M, Zuhlke-Jenisch R, Gesk S, et al. Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the Central nervous system. J Neuropathol Exp Neurol. 2002;61(10):926–933.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen H, Chen L, et al. Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary Central nervous system diffuse large B-cell lymphoma. Medicine (Baltimore). 2019;98(45):e17827.
   PubMedGoogle Scholar
• Hatzl S, Posch F, Deutsch A, et al. Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary Central nervous system lymphoma. Hematol Oncol. 2020;38(3):277–283.
   PubMedGoogle Scholar